Text Size

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000323
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: May 2004
History of Changes
  Purpose

The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.


Condition Phase
Cocaine-Related Disorders
 Phase 1

Study Type: Observational
Study Design: Primary Purpose: Screening
Official Title: Therapeutic Potential of Kappa-Opioids Against Cocaine

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 10
Study Start Date: July 1996
Estimated Study Completion Date: December 1998
  Eligibility

Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

opiate experienced, healthy

Exclusion Criteria:

physical dependence on opioids, barbiturates or alcohol

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000323

Locations
United States, Maryland
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Sharon Walsh, Ph.D. Johns Hopkins University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000323     History of Changes
Other Study ID Numbers: NIDA-10753-1, R01-10753-1
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Analgesics, Opioid
Analgesics
Sensory System Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants

ClinicalTrials.gov processed this record on May 19, 2013